An Oral First-in-Class Small Molecule RSK Inhibitor Suppresses AR Variants and Tumor Growth in Prostate Cancer

Scientists investigated the effect of PMD-026 on YB-1/AR signaling and its antitumor effect in prostate cancer in vitro and in vivo and demonstrated an excellent antitumor effect of the novel ribosomal S6 kinase inhibitor PMD-026 and the combination effect with the antiandrogen enzalutamide in CRPC.